HOBART HIGHLIGHTS

In its first full calendar year of delivering clinical trials, Icon Cancer Centre Hobart continues to increase access to clinical trials for more Tasmanians.

patients recruited clinical trial visits completed

Medical Oncologist, A/Prof Louise Nott and State Clinical Research Coordinator Lead for Tasmania and Victoria, Rossa King, have been instrumental in the consistent activation of new trials and formalisation of research partnerships to grow the portfolio.

Under their leadership, the research team tripled and activated 20 trials and completed over 200 clinical trial visits.

The centre now has the capability to deliver trials across medical oncology and radiation medicine in breast, prostate, skin, genitourinary and lung cancers, specialising across Phase II and III trials.

Phase II and III trials

Specialising in Capability across

• Medical oncology

• Radiation medicine

As Australia’s second highest recruiters to the CANVACCS trial (examining patient perspectives on COVID-19 vaccine), the team co-authored a publication in September 2022 by A/Prof Nott further examining vaccine hesitancy among Australian patients with breast cancer.

Looking ahead, Icon Hobart will continue to build local partnerships and work alongside the public sector to bring more new and emerging treatments to Tasmania.